Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Clinical Trials01:16

Clinical Trials

10.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.1K
Cancer Therapies02:49

Cancer Therapies

9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.

Journal for immunotherapy of cancer·2026
Same author

Circulating tumor DNA-guided response evaluation in patients with previously treated gastroesophageal adenocarcinoma.

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·2026
Same author

Neoadjuvant Single-Cycle Pembrolizumab for Stage I-III MMR-Deficient Colon Cancer: The RESET-C Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Safety and activity of RO7300490, a bispecific CD40 agonist targeted to fibroblast activation protein, in patients with advanced solid tumors: a single-arm, multicenter, first-in-human, phase 1 trial.

Nature cancer·2026
Same author

Histological fidelity and microenvironmental kinome signatures of metastatic patient-derived organoids.

Frontiers in bioengineering and biotechnology·2026
Same author

Cibisatamab and FAP-4-1BBL in microsatellite-stable colorectal cancer: a phase 1b trial.

Nature medicine·2026

Related Experiment Video

Updated: Jan 5, 2026

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

19.1K

[Trends in oncological phase I trials].

Kristoffer Staal Rohrberg1, Camilla Qvortrup, Martin Højgaard

  • 1kristoffer.staal.rohrberg@regionh.dk.

Ugeskrift for Laeger
|October 16, 2019
PubMed
Summary

This review highlights the evolution of anticancer therapies, moving beyond cytotoxic drugs to targeted agents and immunotherapy. Genomic testing is increasingly integrated into clinical trials for personalized cancer treatment.

Area of Science:

  • Oncology
  • Pharmacology
  • Genomics

Background:

  • The development of anticancer therapies has significantly evolved.
  • Classical cytotoxic chemotherapy is being complemented by novel therapeutic strategies.
  • Over 1,100 cancer drugs are in development in the United States.

Purpose of the Study:

  • To summarize current knowledge on anticancer therapy development.
  • To highlight the shift towards targeted agents and immunotherapy.
  • To discuss the increasing role of genomic alterations and testing in cancer treatment.

Main Methods:

  • Review of current scientific literature and drug development pipelines.
  • Analysis of trends in anticancer drug discovery and clinical trials.
  • Focus on advancements in targeted therapy and immunotherapy.

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.7K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

12.1K

Related Experiment Videos

Last Updated: Jan 5, 2026

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence
07:54

Heterogeneity Mapping of Protein Expression in Tumors using Quantitative Immunofluorescence

Published on: October 25, 2011

19.1K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.7K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

12.1K

Main Results:

  • Anticancer drug development has shifted from cytotoxic agents to targeted therapies and immunotherapies.
  • Targeted agents show efficacy in tumors with specific genomic alterations.
  • Personalized immunotherapy approaches are under development.
  • Genomic testing is increasingly incorporated into early clinical oncology trials.

Conclusions:

  • The landscape of anticancer therapy is rapidly advancing with new biological insights.
  • Targeted agents and immunotherapy represent a significant paradigm shift in cancer treatment.
  • Integration of genomic data is crucial for developing effective and personalized anticancer strategies.